payor coverage
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
Top Five Articles on 360Dx Last Week: Delayed Non-Coverage Decisions for Some Genetic Tests; More
Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.
In Brief This Week: Natera, Becton Dickinson, Tempus, T2 Biosystems, Bio-Rad, More
News items for the week of Dec. 16, 2024.
Myriad Genetics Stock Tanks After UnitedHealthcare Pulls Coverage of PGx Panels
The payor had been covering Myriad's GeneSight assay since 2019 but has decided there is not enough evidence showing this type of test is medically necessary.
In Brief This Week: ADLM, Labcorp, Foresight Diagnostics, T2 Biosystems, More
News items for the week of Oct. 7, 2024.
Jul 25, 2023
Sep 27, 2021
Jul 6, 2021